Abstract
Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small volume biological pharmaceuticals. In recent times, Australia has made incremental changes to its regulation of biosimilars – in patent registration, in the use of commercial confidential information, and in remuneration. These improvements, together with Australia’s geographical proximity and strong trade relationship with the Asian biocluster, have positioned Australia to take advantage of potential public cost savings from the increased use of biosimilars.
Original language | English |
---|---|
Pages (from-to) | 184-187 |
Number of pages | 4 |
Journal | Generics and Biosimilars Initiative Journal |
Volume | 3 |
Issue number | 4 |
Publication status | Published - 2014 |
Keywords
- Australia
- biosimilars
- confidential business information
- patents